Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Sarah Milgrom

Concepts (370)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease
42
2026
173
11.990
Why?
Radiotherapy, Intensity-Modulated
17
2026
143
4.060
Why?
Positron Emission Tomography Computed Tomography
17
2026
122
3.750
Why?
Radiotherapy
15
2026
209
2.380
Why?
Fluorodeoxyglucose F18
8
2026
164
2.290
Why?
Tumor Burden
7
2026
326
2.280
Why?
Radiotherapy Planning, Computer-Assisted
16
2026
150
2.260
Why?
Antineoplastic Combined Chemotherapy Protocols
35
2026
1998
2.240
Why?
Lymphoma
10
2025
251
2.030
Why?
Whole-Body Irradiation
3
2026
73
1.880
Why?
Radiation Injuries
9
2025
149
1.870
Why?
Radiotherapy Dosage
18
2026
289
1.680
Why?
Central Nervous System Neoplasms
9
2021
177
1.670
Why?
Radiopharmaceuticals
6
2023
210
1.570
Why?
Hematologic Neoplasms
2
2026
170
1.520
Why?
Neoplasm Staging
32
2026
1488
1.430
Why?
Lymphoma, Non-Hodgkin
6
2024
124
1.430
Why?
Lymphoma, Large B-Cell, Diffuse
8
2024
195
1.250
Why?
Neoplasms
9
2026
2954
1.200
Why?
Sarcoma
2
2023
209
1.170
Why?
Salvage Therapy
11
2024
166
1.150
Why?
Neoplasm Recurrence, Local
13
2023
1160
1.150
Why?
Mediastinal Neoplasms
5
2021
54
1.070
Why?
Endometrial Neoplasms
4
2014
205
1.070
Why?
Prognosis
24
2026
4351
1.040
Why?
Combined Modality Therapy
22
2024
1271
1.020
Why?
Hematopoietic Stem Cell Transplantation
7
2024
704
1.010
Why?
Radiotherapy, Adjuvant
7
2024
222
0.960
Why?
Humans
126
2026
146342
0.960
Why?
Lymphoma, Extranodal NK-T-Cell
1
2026
11
0.930
Why?
Proton Therapy
3
2026
16
0.920
Why?
Positron-Emission Tomography
9
2025
343
0.920
Why?
Neoplasms, Radiation-Induced
2
2026
100
0.920
Why?
Rhabdomyosarcoma
2
2024
65
0.910
Why?
Neoplasms, Second Primary
2
2026
103
0.890
Why?
Sarcoma, Ewing
2
2024
103
0.880
Why?
Doxorubicin
15
2026
416
0.850
Why?
Child
31
2026
22693
0.830
Why?
Disease Progression
7
2024
2867
0.830
Why?
Young Adult
37
2026
14330
0.790
Why?
Radiation
2
2020
24
0.790
Why?
Clinical Trials as Topic
2
2026
1064
0.790
Why?
Craniopharyngioma
1
2024
77
0.780
Why?
Radiation Exposure
1
2023
62
0.750
Why?
Pituitary Neoplasms
1
2024
190
0.730
Why?
Adolescent
35
2026
22557
0.720
Why?
Adenocarcinoma
3
2014
927
0.720
Why?
Lymphoma, Follicular
5
2020
57
0.720
Why?
Salivary Glands
2
2021
36
0.710
Why?
Smiling
1
2021
6
0.700
Why?
Xerostomia
1
2021
13
0.680
Why?
Retrospective Studies
39
2026
17438
0.670
Why?
Bleomycin
10
2026
255
0.670
Why?
Tooth Abnormalities
1
2021
17
0.670
Why?
Brachytherapy
1
2021
132
0.640
Why?
Chemoradiotherapy
9
2021
238
0.620
Why?
Face
1
2021
177
0.620
Why?
Cancer Survivors
2
2026
348
0.610
Why?
Aged, 80 and over
23
2026
8391
0.600
Why?
Vinblastine
9
2025
75
0.600
Why?
Intraocular Lymphoma
2
2016
3
0.590
Why?
Dacarbazine
9
2025
98
0.590
Why?
Aged
43
2026
26432
0.580
Why?
Adult
54
2026
41087
0.580
Why?
Infertility, Female
2
2025
124
0.570
Why?
Middle Aged
51
2026
36619
0.560
Why?
Lymphoma, B-Cell, Marginal Zone
4
2019
21
0.560
Why?
Organs at Risk
4
2026
37
0.560
Why?
Rectal Neoplasms
3
2016
160
0.550
Why?
Female
65
2026
79499
0.550
Why?
Cerebellar Neoplasms
1
2020
169
0.530
Why?
Radiotherapy, Image-Guided
4
2026
40
0.530
Why?
Medulloblastoma
1
2020
208
0.520
Why?
Breast Neoplasms
6
2026
2418
0.520
Why?
Recurrence
9
2020
1133
0.500
Why?
Male
57
2026
73396
0.500
Why?
Meningeal Neoplasms
1
2018
95
0.490
Why?
Leukemia, Biphenotypic, Acute
1
2016
4
0.490
Why?
Leukemia, Myeloid, Acute
2
2023
702
0.480
Why?
Treatment Outcome
27
2026
11821
0.470
Why?
Patient Satisfaction
1
2020
706
0.470
Why?
Head and Neck Neoplasms
1
2021
563
0.460
Why?
Mediastinum
4
2026
23
0.440
Why?
Graft vs Host Disease
2
2024
283
0.440
Why?
Radiation Oncology
2
2026
83
0.430
Why?
Eye Diseases
1
2016
100
0.430
Why?
Brain Neoplasms
3
2023
1325
0.430
Why?
Lower Urinary Tract Symptoms
2
2026
62
0.430
Why?
Follow-Up Studies
16
2025
5439
0.420
Why?
Survival Rate
12
2021
2092
0.410
Why?
Vincristine
6
2026
148
0.400
Why?
Disease-Free Survival
12
2020
778
0.400
Why?
Glycolysis
3
2023
342
0.390
Why?
Endometrium
1
2013
64
0.390
Why?
Peritoneal Cavity
1
2013
30
0.390
Why?
Palate, Hard
1
2012
5
0.380
Why?
Digestive System Surgical Procedures
1
2014
115
0.380
Why?
Cyclophosphamide
5
2026
275
0.370
Why?
Stomach Neoplasms
3
2019
128
0.370
Why?
Chemoradiotherapy, Adjuvant
3
2019
44
0.370
Why?
Lymphoma, B-Cell
3
2021
150
0.370
Why?
Child, Preschool
10
2026
11913
0.370
Why?
Mastectomy, Simple
1
2012
1
0.360
Why?
Image Enhancement
1
2013
198
0.360
Why?
Neoadjuvant Therapy
2
2016
475
0.350
Why?
Sentinel Lymph Node Biopsy
1
2012
118
0.340
Why?
Carcinoma, Lobular
1
2012
59
0.340
Why?
Carcinoma, Ductal, Breast
1
2012
92
0.340
Why?
Prednisone
4
2026
229
0.330
Why?
Adrenal Gland Neoplasms
1
2012
99
0.330
Why?
Radiotherapy, Conformal
2
2026
75
0.320
Why?
Rituximab
4
2026
208
0.310
Why?
Biopsy
6
2020
1075
0.310
Why?
Disease Management
6
2019
651
0.300
Why?
Cellulitis
1
2009
55
0.290
Why?
Tomography, X-Ray Computed
7
2023
2786
0.290
Why?
Antineoplastic Agents
6
2025
2219
0.290
Why?
Carcinoma, Squamous Cell
1
2014
628
0.280
Why?
Kaplan-Meier Estimate
7
2020
970
0.280
Why?
United States
6
2026
16136
0.280
Why?
Lymphocytes
3
2020
379
0.280
Why?
Lymphoma, Mantle-Cell
2
2019
36
0.270
Why?
Organ Sparing Treatments
2
2026
37
0.260
Why?
Coronary Artery Disease
2
2026
751
0.250
Why?
Consensus
3
2024
467
0.250
Why?
Survival Analysis
6
2020
1378
0.240
Why?
Cardiotoxicity
2
2023
35
0.240
Why?
Lung Neoplasms
3
2026
2675
0.240
Why?
Pregnancy Complications, Neoplastic
2
2017
64
0.240
Why?
Ifosfamide
1
2026
39
0.240
Why?
Testicular Neoplasms
2
2018
108
0.230
Why?
Credentialing
1
2026
21
0.230
Why?
Radiation Pneumonitis
2
2016
31
0.230
Why?
Multiple Myeloma
2
2020
310
0.230
Why?
Patient Selection
2
2022
728
0.230
Why?
Pelvic Neoplasms
1
2025
24
0.230
Why?
Heart
3
2018
626
0.220
Why?
Urinary Tract
1
2025
47
0.220
Why?
Urodynamics
1
2025
44
0.220
Why?
Lymph Node Excision
2
2019
174
0.220
Why?
Antimetabolites, Antineoplastic
2
2017
108
0.210
Why?
Risk Factors
6
2026
10921
0.210
Why?
Risk Assessment
6
2023
3712
0.210
Why?
Leukemia
2
2017
246
0.210
Why?
Transplantation, Haploidentical
1
2024
23
0.210
Why?
Central Nervous System
3
2021
278
0.200
Why?
Magnetic Resonance Imaging
4
2019
3926
0.200
Why?
Uterus
1
2025
227
0.200
Why?
Quality Assurance, Health Care
1
2025
349
0.200
Why?
Lymphadenopathy
1
2023
8
0.190
Why?
Lymphatic Metastasis
3
2014
335
0.190
Why?
Virtual Reality
1
2025
83
0.190
Why?
Cord Blood Stem Cell Transplantation
1
2024
103
0.190
Why?
Comprehension
1
2025
175
0.190
Why?
Transplantation Conditioning
1
2024
193
0.190
Why?
Neoplasm Grading
4
2019
313
0.190
Why?
Remission Induction
3
2018
308
0.180
Why?
Protons
2
2020
96
0.180
Why?
Brain Stem Neoplasms
1
2023
86
0.180
Why?
Bone Neoplasms
1
2024
272
0.170
Why?
Radiometry
2
2019
56
0.170
Why?
Mitogen-Activated Protein Kinase 7
1
2021
16
0.170
Why?
Gastric Mucosa
2
2019
54
0.170
Why?
Chemotherapy, Adjuvant
2
2013
429
0.170
Why?
Cohort Studies
6
2024
6077
0.170
Why?
Transplantation, Autologous
3
2018
306
0.170
Why?
Societies, Medical
1
2026
907
0.170
Why?
Survivors
2
2023
526
0.170
Why?
Multimodal Imaging
3
2017
137
0.170
Why?
Poly(ADP-ribose) Polymerases
1
2021
88
0.170
Why?
Radium
1
2020
4
0.170
Why?
Imaging, Three-Dimensional
1
2025
582
0.160
Why?
Breath Holding
2
2017
10
0.160
Why?
Postoperative Complications
1
2014
3034
0.160
Why?
Long Term Adverse Effects
1
2020
13
0.160
Why?
Artificial Intelligence
1
2025
389
0.160
Why?
Cranial Irradiation
2
2023
85
0.160
Why?
Etoposide
4
2026
169
0.160
Why?
Patient Education as Topic
1
2025
770
0.150
Why?
Skin Neoplasms
2
2018
806
0.150
Why?
Stem Cell Transplantation
2
2018
190
0.150
Why?
Plasmacytoma
1
2019
19
0.150
Why?
Cardiology
1
2022
363
0.140
Why?
CD4-CD8 Ratio
1
2018
23
0.140
Why?
Postoperative Care
2
2019
301
0.140
Why?
Radiation Dosage
1
2020
193
0.140
Why?
Mycosis Fungoides
1
2018
63
0.140
Why?
Prospective Studies
6
2026
8123
0.140
Why?
Methotrexate
2
2017
234
0.140
Why?
Electrons
1
2018
82
0.140
Why?
Breast Neoplasms, Male
1
2018
29
0.140
Why?
Glioma
1
2023
425
0.140
Why?
Area Under Curve
1
2019
335
0.130
Why?
Peritoneal Neoplasms
1
2019
103
0.130
Why?
Radiotherapy Setup Errors
1
2017
3
0.130
Why?
Platelet Count
1
2017
95
0.130
Why?
Autografts
1
2018
56
0.130
Why?
Hypothyroidism
1
2018
68
0.130
Why?
Craniospinal Irradiation
1
2017
5
0.130
Why?
Biomarkers
5
2026
4340
0.130
Why?
Dendritic Cell Sarcoma, Follicular
1
2017
4
0.130
Why?
Leukocyte Count
1
2017
321
0.130
Why?
Eye Neoplasms
1
2017
31
0.130
Why?
Osteogenesis Imperfecta
2
2007
14
0.120
Why?
Uncertainty
1
2017
145
0.120
Why?
Spinal Cord Diseases
1
2017
42
0.120
Why?
Pentostatin
1
2016
4
0.120
Why?
Neoplasm, Residual
1
2017
143
0.120
Why?
Axilla
2
2017
51
0.120
Why?
Photopheresis
1
2016
9
0.120
Why?
Predictive Value of Tests
3
2022
2113
0.120
Why?
Methylprednisolone
1
2016
58
0.120
Why?
Plasmablastic Lymphoma
1
2015
8
0.120
Why?
Radiographic Image Interpretation, Computer-Assisted
1
2016
121
0.120
Why?
Confidence Intervals
1
2016
329
0.120
Why?
Collagen Type I
2
2007
144
0.120
Why?
Fatal Outcome
1
2016
302
0.110
Why?
Caregivers
2
2025
1080
0.110
Why?
Abortion, Spontaneous
1
2016
120
0.110
Why?
Antibiotics, Antineoplastic
1
2016
141
0.110
Why?
Congenital Abnormalities
1
2016
108
0.110
Why?
Hysterectomy
2
2013
139
0.110
Why?
Anxiety
1
2023
1125
0.110
Why?
Tacrolimus
1
2016
192
0.110
Why?
Transplantation, Homologous
1
2016
416
0.110
Why?
Drug Resistance, Neoplasm
2
2019
893
0.110
Why?
Proportional Hazards Models
4
2020
1331
0.110
Why?
Blood Platelets
1
2017
382
0.100
Why?
Receptors, Progesterone
2
2014
242
0.100
Why?
Risk
1
2016
920
0.100
Why?
Age Factors
1
2021
3347
0.100
Why?
Kidney Neoplasms
1
2018
419
0.100
Why?
Receptors, Estrogen
2
2014
406
0.090
Why?
Carboplatin
1
2013
168
0.090
Why?
Spinal Cord
1
2015
378
0.090
Why?
Anti-Inflammatory Agents
1
2016
474
0.090
Why?
Fluorouracil
1
2013
231
0.090
Why?
Lung
2
2016
4122
0.090
Why?
Pelvis
1
2013
129
0.090
Why?
Carcinoma, Non-Small-Cell Lung
1
2021
1195
0.090
Why?
Paclitaxel
1
2013
260
0.090
Why?
Immunoenzyme Techniques
1
2012
197
0.090
Why?
Immunohistochemistry
1
2016
1712
0.090
Why?
Neutrophils
1
2017
1133
0.090
Why?
Immunosuppressive Agents
1
2016
829
0.090
Why?
Health Knowledge, Attitudes, Practice
1
2020
1408
0.090
Why?
Cisplatin
1
2013
347
0.080
Why?
Triple Negative Breast Neoplasms
1
2014
220
0.080
Why?
Brain
2
2020
2991
0.080
Why?
Models, Biological
1
2018
1761
0.080
Why?
Immunotherapy
1
2015
671
0.080
Why?
Contrast Media
1
2013
493
0.080
Why?
Polymorphism, Single Nucleotide
1
2016
2240
0.070
Why?
Patient Compliance
1
2013
589
0.070
Why?
Dose-Response Relationship, Radiation
2
2020
141
0.070
Why?
Liver Neoplasms
1
2014
776
0.070
Why?
Antibodies, Monoclonal, Murine-Derived
2
2019
96
0.070
Why?
Cytarabine
2
2018
66
0.060
Why?
Biomarkers, Tumor
1
2014
1339
0.060
Why?
Integrins
1
2007
88
0.060
Why?
Nerve Growth Factor
1
2026
36
0.060
Why?
Proteoglycans
1
2007
111
0.060
Why?
Practice Guidelines as Topic
1
2014
1591
0.060
Why?
Colorectal Neoplasms
1
2014
874
0.060
Why?
Time Factors
4
2018
7109
0.060
Why?
Treatment Failure
2
2018
361
0.060
Why?
Amino Acid Substitution
1
2006
297
0.060
Why?
Brain-Derived Neurotrophic Factor
1
2026
155
0.060
Why?
Glycine
1
2006
184
0.060
Why?
Neoplasm Invasiveness
2
2017
504
0.050
Why?
Fertility Preservation
1
2025
57
0.050
Why?
Clinical Decision-Making
2
2019
365
0.050
Why?
Creatinine
1
2026
511
0.050
Why?
American Heart Association
1
2026
364
0.050
Why?
X-ray Repair Cross Complementing Protein 1
1
2023
14
0.050
Why?
Intelligence Tests
1
2023
55
0.050
Why?
Adenosine Triphosphate
1
2026
494
0.050
Why?
Standard of Care
1
2024
81
0.050
Why?
X-Rays
1
2023
27
0.050
Why?
Cell- and Tissue-Based Therapy
1
2024
82
0.050
Why?
Regression Analysis
2
2016
999
0.050
Why?
Proto-Oncogene Proteins c-sis
1
2023
38
0.050
Why?
Analysis of Variance
2
2016
1298
0.050
Why?
Pregnancy
3
2025
7230
0.050
Why?
Inducible T-Cell Co-Stimulator Protein
1
2022
12
0.050
Why?
Cytidine Deaminase
1
2023
59
0.050
Why?
Phenotype
3
2021
3206
0.050
Why?
Terminology as Topic
1
2024
253
0.050
Why?
Brain Stem
1
2023
101
0.040
Why?
Ribose
1
2021
21
0.040
Why?
Adenosine Diphosphate
1
2021
75
0.040
Why?
Troponin T
1
2021
63
0.040
Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
55
0.040
Why?
Feedback
1
2021
183
0.040
Why?
Radiosurgery
1
2024
398
0.040
Why?
Immunotherapy, Adoptive
1
2024
356
0.040
Why?
Automation
1
2020
104
0.040
Why?
Risk Management
1
2020
81
0.040
Why?
Prevalence
2
2016
2861
0.040
Why?
Incidence
2
2016
2936
0.040
Why?
Mesentery
1
2019
44
0.040
Why?
Infant
2
2025
10114
0.040
Why?
Workflow
1
2020
182
0.030
Why?
Neuropsychological Tests
1
2023
1149
0.030
Why?
Busulfan
1
2018
15
0.030
Why?
Respiration
1
2019
208
0.030
Why?
Safety
1
2020
347
0.030
Why?
Melphalan
1
2018
43
0.030
Why?
Carmustine
1
2018
52
0.030
Why?
Algorithms
1
2025
1849
0.030
Why?
Inhalation
1
2017
28
0.030
Why?
Cone-Beam Computed Tomography
1
2017
32
0.030
Why?
Breast
1
2018
155
0.030
Why?
Subacute Combined Degeneration
1
2017
1
0.030
Why?
Phosphorylation
1
2021
1724
0.030
Why?
Photons
1
2017
67
0.030
Why?
Injections, Spinal
1
2017
120
0.030
Why?
Deoxycytidine
1
2018
219
0.030
Why?
New York
1
2016
128
0.030
Why?
Orbit
1
2017
67
0.030
Why?
Time-to-Treatment
1
2019
257
0.030
Why?
Homocysteine
1
2017
152
0.030
Why?
Lymph Nodes
1
2019
511
0.030
Why?
Procarbazine
1
2015
9
0.030
Why?
Genetic Markers
1
2016
340
0.030
Why?
Observer Variation
1
2016
356
0.030
Why?
Transforming Growth Factor beta1
1
2016
176
0.030
Why?
Mutation
1
2007
4093
0.030
Why?
Folic Acid
1
2017
197
0.030
Why?
Texas
1
2016
280
0.030
Why?
Animals
2
2021
38107
0.030
Why?
Molecular Targeted Therapy
1
2018
447
0.030
Why?
Mitochondria
1
2021
997
0.030
Why?
Secondary Prevention
1
2016
248
0.030
Why?
Gastrointestinal Diseases
1
2016
220
0.030
Why?
Diagnostic Imaging
1
2017
340
0.030
Why?
Abortion, Induced
1
2016
112
0.030
Why?
Drug Administration Schedule
1
2016
790
0.030
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
299
0.020
Why?
Pregnancy Outcome
1
2017
503
0.020
Why?
Acute Disease
1
2016
1038
0.020
Why?
Postpartum Period
1
2016
377
0.020
Why?
Multivariate Analysis
1
2016
1543
0.020
Why?
Diagnosis, Differential
1
2017
1503
0.020
Why?
CD8-Positive T-Lymphocytes
1
2018
931
0.020
Why?
Mastectomy
1
2014
189
0.020
Why?
Ultrasonography
1
2016
788
0.020
Why?
CD4-Positive T-Lymphocytes
1
2018
1150
0.020
Why?
Surveys and Questionnaires
1
2025
6073
0.020
Why?
Ovariectomy
1
2012
164
0.020
Why?
Medical Oncology
1
2014
345
0.020
Why?
Comorbidity
1
2016
1665
0.020
Why?
Severity of Illness Index
1
2019
2921
0.020
Why?
Diet
1
2017
1273
0.020
Why?
Kidney
1
2017
1498
0.020
Why?
Quality of Life
1
2021
3200
0.020
Why?
Reproducibility of Results
1
2016
3416
0.020
Why?
Electronic Health Records
1
2017
1210
0.020
Why?
Anti-Bacterial Agents
1
2019
1942
0.020
Why?
Genetic Predisposition to Disease
1
2016
2488
0.020
Why?
Electrophoresis
1
2006
31
0.020
Why?
Case-Control Studies
1
2014
3647
0.010
Why?
DNA Mutational Analysis
1
2007
410
0.010
Why?
Databases, Genetic
1
2007
239
0.010
Why?
Protein Structure, Tertiary
1
2007
834
0.010
Why?
Collagen
1
2007
460
0.010
Why?
Mice
1
2021
18297
0.010
Why?
Binding Sites
1
2007
1309
0.010
Why?
Protein Binding
1
2007
2244
0.010
Why?
Cells, Cultured
1
2006
4118
0.010
Why?
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)